MedTrace Logo

Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer

NCT02450032 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-05-21

No results posted yet for this study

Summary

This study was designed to investigate the antibody response generated by a 500µg dose of G17DT in patients with gastric cancer.

Conditions

Interventions

BIOLOGICAL

G17DT

Sponsors & Collaborators

  • Cancer Advances Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Stuart, MB ChB · Glasgow Royal Infirmary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-02-29
Primary Completion
2001-05-31
Completion
2001-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02450032 on ClinicalTrials.gov